KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teladoc Health (TDOC) Cash & Equivalents (2016 - 2026)

Teladoc Health's Cash & Equivalents history spans 14 years, with the latest figure at $750.7 million for Q1 2026.

  • On a quarterly basis, Cash & Equivalents fell 37.09% to $750.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $750.7 million, a 37.09% decrease, with the full-year FY2025 number at $781.1 million, down 39.84% from a year prior.
  • Cash & Equivalents hit $750.7 million in Q1 2026 for Teladoc Health, down from $781.1 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for TDOC hit a ceiling of $1.3 billion in Q4 2024 and a floor of $679.6 million in Q2 2025.
  • Historically, Cash & Equivalents has averaged $968.8 million across 5 years, with a median of $918.2 million in 2022.
  • Biggest five-year swings in Cash & Equivalents: grew 23.56% in 2024 and later tumbled 41.61% in 2025.
  • Tracing TDOC's Cash & Equivalents over 5 years: stood at $918.2 million in 2022, then rose by 22.38% to $1.1 billion in 2023, then rose by 15.54% to $1.3 billion in 2024, then tumbled by 39.84% to $781.1 million in 2025, then fell by 3.89% to $750.7 million in 2026.
  • Business Quant data shows Cash & Equivalents for TDOC at $750.7 million in Q1 2026, $781.1 million in Q4 2025, and $726.2 million in Q3 2025.